Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,456 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,550 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07011342 | Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment(SCOUT) | recruiting | N/A | 70 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06705686 | Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer(PHAROS) | recruiting | Phase 1 | 40 | TechnoGenesys, Inc.INDUSTRY | 1 | Mar 20, 2026 |
| NCT03594760 | PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer | recruiting | Phase 3 | 1,000 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers(THUNDER) | recruiting | Phase 2 / Phase 3 | 493 | Cancer Research AntwerpOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04895839 | Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program(PC-PEP) | recruiting | N/A | 2,130 | Gabriela IlieOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05435495 | Mechanisms of Resistance to PSMA Radioligand Therapy | recruiting | — | 125 | University of California, San FranciscoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07398690 | INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis(INSIGHT-PCa) | recruiting | N/A | 1,432 | In Gab Jeong, MDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06555588 | Engage Psychosocial Intervention for Cancer Symptoms(Engage) | recruiting | N/A | 190 | Duke UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06966778 | Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial | recruiting | N/A | 135 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07245745 | Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer | recruiting | N/A | 188 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07422597 | Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer(PRORAND) | recruiting | N/A | 1,016 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | recruiting | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06835218 | PROCARE - PROstate Cancer Real World Evidence Registry(PROCARE) | recruiting | — | 5,000 | UroTrials Company (GmbH)NETWORK | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07460843 | Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis | recruiting | N/A | 592 | Peking University First HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03424850 | Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy | recruiting | Phase 1 / Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06437574 | Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer | recruiting | Phase 2 | 140 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07090148 | Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC | recruiting | Phase 1 | 14 | University of Wisconsin, MadisonOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | recruiting | Phase 2 | 90 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07164027 | Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07188064 | A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery(PRP NG PRO M) | recruiting | N/A | 100 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04083937 | Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies(PAROS) | recruiting | N/A | 897 | University Hospital HeidelbergOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05396872 | Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer | recruiting | N/A | 250 | University of California, San FranciscoOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07182279 | Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 29 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06985238 | Stratagen Quantitative Prostate MRI Platform Pilot Study | recruiting | N/A | 75 | Stratagen Bio, Inc.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04228211 | Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation(UPC) | recruiting | — | 1,500 | UMC UtrechtOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04861194 | EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)(ERECT) | recruiting | N/A | 70 | UMC UtrechtOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06130995 | Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | recruiting | Phase 1 | 46 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02997709 | Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients(COMBINE) | recruiting | — | 144 | University of MiamiOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05586360 | T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06171269 | Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life | recruiting | N/A | 60 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07088536 | Occupational Situation and Return to Work of Urological Patients(OCCURORTW) | recruiting | — | 2,000 | Jagiellonian UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07230106 | A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | recruiting | Phase 2 | 218 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03495427 | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | recruiting | Phase 2 / Phase 3 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06237179 | Behavioral Exercise Training to Reduce Cardiovascular Disease Risk(EXTRA-PC) | recruiting | Phase 1 / Phase 2 | 60 | Virginia Commonwealth UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05295407 | Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy(GenBx) | recruiting | — | 1,000 | Endeavor HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05879913 | ASCVD Management Using CCTA in Prostate Cancer Patients on ADT | recruiting | N/A | 100 | Indiana UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432360 | Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology | recruiting | — | 300 | Virdx, Inc.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07369570 | Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging(REMRI) | recruiting | N/A | 100 | University of Eastern FinlandOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 23, 2026source: clinicaltrials